Market Cap 72.15M
Revenue (ttm) 0.00
Net Income (ttm) -28.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 450,500
Avg Vol 793,034
Day's Range N/A - N/A
Shares Out 44.54M
Stochastic %K 46%
Beta -0.83
Analysts Strong Sell
Price Target $8.50

Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone l...

Industry: Biotechnology
Sector: Healthcare
Phone: 410 297 7793
Address:
115 Pullman Crossing Road, Suite 103, Grasonville, United States
gabriel6748
gabriel6748 Jul. 15 at 9:37 AM
$OSTX VAMOOOS! Lets gooooo! https://www.mmm-online.com/news/animal-pharma-70b-story-to-tell/ https://x.com/ostherapies/status/2077109498934607950?s=46
0 · Reply
Bangerstocksbuyer
Bangerstocksbuyer Jul. 14 at 11:55 PM
$OSTX Looking to start a position here any opinions of how derisked it is?
1 · Reply
TeaBaggerVance
TeaBaggerVance Jul. 14 at 9:43 PM
$OSTX Potential Catalyst Calendar 📅 Jul 21-Aug 8: FDA Type B Statistical Methods Meeting Potential Reaction: +15% to +40% if FDA aligns on biomarkers & 3-year OS strategy. 📅 Late Jul-Aug: FDA Meeting Results PR Potential Reaction: +10% to +30% if management confirms a clear Accelerated Approval pathway. 📅 Late Aug-Early Sep: Pre-BLA FDA Meeting Potential Reaction: +20% to +100%+ if FDA provides positive feedback and no major issues. 📅 Early-Mid Sep: 3-Year Interim Overall Survival Data Potential Reaction: +30% to +100%+ if efficacy remains statistically compelling. 📅 Late Sep: EMA Submission + Australia Phase 3 Initiation Potential Reaction: +10% to +25% as global regulatory progress is validated. 📅 Oct-Nov: Additional FDA/BLA Updates Potential Reaction: +10% to +30% depending on the nature of the update. 📅 Nov-Dec: Accelerated Approval BLA Submission Potential Reaction: +20% to +60% as the company reaches a major regulatory milestone. These are just specific to OST-HER2 😲
4 · Reply
smallpower17
smallpower17 Jul. 14 at 6:22 PM
$OSTX $BCTX OSTX and BCTX are my two picks to skyrocket between now and the end of the year. Each has a survival rate catalyst due in the 2nd half of 2026, and both look highly likely to achieve their clinical targets and get approved. Also, both have secured cash runways to get them into 2027.
0 · Reply
VinEuro
VinEuro Jul. 14 at 2:06 PM
$OSTX What is the bull-case out here, does anyone has an overview of te potential catalyst (add on my DD)
2 · Reply
Indycolts2004
Indycolts2004 Jul. 14 at 11:28 AM
0 · Reply
Wyoming2
Wyoming2 Jul. 13 at 2:29 PM
0 · Reply
cwork
cwork Jul. 13 at 2:27 PM
$OSTX https://ir.ostherapies.com/news-events/press-releases/detail/118/os-animal-health-announces-peer-reviewed-publication-of
0 · Reply
Greenbackisback
Greenbackisback Jul. 13 at 12:06 AM
$OSTX ok let’s start to make it happen this week! I am ramped up on shares and amped up!
0 · Reply
ACstranger
ACstranger Jul. 12 at 10:30 AM
$OSTX Companies do this to align with the FDA early on. By getting FDA alignment on PD biomarkers through the BEST Glossary, a company can often use these biomarkers as "surrogate endpoints" (substitute measures for clinical benefits). This can significantly shorten clinical trial times and strengthen applications for faster regulatory approvals (such as an Accelerated Approval pathway).
0 · Reply
Latest News on OSTX
OS Therapies initiated with a Buy at Roth Capital

2026-07-09T10:40:49.000Z - 6 days ago

OS Therapies initiated with a Buy at Roth Capital


OS Therapies Third Quarter 2026 Corporate Outlook

Jul 6, 2026, 9:00 AM EDT - 8 days ago

OS Therapies Third Quarter 2026 Corporate Outlook


OS Therapies Appoints Dr. Craig Eagle to Board of Directors

Jul 2, 2026, 7:30 AM EDT - 12 days ago

OS Therapies Appoints Dr. Craig Eagle to Board of Directors


OS Therapies Provides U.S. Regulatory Update

Jun 30, 2026, 7:40 AM EDT - 14 days ago

OS Therapies Provides U.S. Regulatory Update


OS Therapies Quarterly report: Q1 2026

May 18, 2026, 7:00 AM EDT - 2 months ago

OS Therapies Quarterly report: Q1 2026


OS Therapies Earnings release: Q1 2026

May 18, 2026, 7:00 AM EDT - 2 months ago

OS Therapies Earnings release: Q1 2026


OS Therapies Appoints Craig Eagle, MD as Strategic Advisor

Apr 8, 2026, 11:38 AM EDT - 3 months ago

OS Therapies Appoints Craig Eagle, MD as Strategic Advisor


OS Therapies Earnings release: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 3 months ago

OS Therapies Earnings release: Q4 2025


OS Therapies Annual report: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 3 months ago

OS Therapies Annual report: Q4 2025


OS Therapies Enters into Warrant Inducement Agreements

Jan 12, 2026, 8:01 AM EST - 6 months ago

OS Therapies Enters into Warrant Inducement Agreements


OS Therapies Provides First Half 2026 Corporate Outlook

Jan 5, 2026, 7:40 AM EST - 6 months ago

OS Therapies Provides First Half 2026 Corporate Outlook


OS Therapies Transcript: Life Sciences Virtual Investor Forum 2025

Dec 11, 2025, 10:30 AM EST - 7 months ago

OS Therapies Transcript: Life Sciences Virtual Investor Forum 2025


OS Therapies Slides: Corporate presentation

Dec 10, 2025, 7:00 AM EST - 7 months ago

OS Therapies Slides: Corporate presentation


OS Therapies Earnings release: Q3 2025

Nov 14, 2025, 4:00 PM EST - 8 months ago

OS Therapies Earnings release: Q3 2025


OS Therapies Quarterly report: Q3 2025

Nov 14, 2025, 4:00 PM EST - 8 months ago

OS Therapies Quarterly report: Q3 2025


OS Therapies Proxy statement: Proxy Filing

Oct 17, 2025, 8:00 AM EDT - 9 months ago

OS Therapies Proxy statement: Proxy Filing


OS Therapies to Participate in Fall 2025 Conferences and Events

Oct 7, 2025, 11:50 AM EDT - 10 months ago

OS Therapies to Participate in Fall 2025 Conferences and Events


OS Therapies Proxy statement: Proxy Filing

Aug 25, 2025, 8:00 AM EDT - 11 months ago

OS Therapies Proxy statement: Proxy Filing


OS Therapies Proxy statement: Proxy Filing

Aug 25, 2025, 8:00 AM EDT - 11 months ago

OS Therapies Proxy statement: Proxy Filing


OS Therapies Quarterly report: Q2 2025

Aug 18, 2025, 6:00 PM EDT - 11 months ago

OS Therapies Quarterly report: Q2 2025


OS Therapies Earnings release: Q2 2025

Aug 18, 2025, 6:00 PM EDT - 11 months ago

OS Therapies Earnings release: Q2 2025


OS Therapies Proxy statement: Proxy Filing

Aug 15, 2025, 8:00 AM EDT - 11 months ago

OS Therapies Proxy statement: Proxy Filing


OS Therapies files $100M mixed securities shelf

2025-08-08T20:50:15.000Z - 1 year ago

OS Therapies files $100M mixed securities shelf


OS Therapies Registration statement: Registration Filing

Aug 8, 2025, 8:00 AM EDT - 1 year ago

OS Therapies Registration statement: Registration Filing


OS Therapies Registration statement: Registration Filing

Aug 4, 2025, 8:00 AM EDT - 1 year ago

OS Therapies Registration statement: Registration Filing


OS Therapies Registration statement: Registration Filing

May 23, 2025, 8:00 AM EDT - 1 year ago

OS Therapies Registration statement: Registration Filing


OS Therapies reports Q1 EPS (18c), consensus (8c)

2025-05-16T10:05:35.000Z - 1 year ago

OS Therapies reports Q1 EPS (18c), consensus (8c)


OS Therapies Inc trading resumes

2025-05-07T13:15:18.000Z - 1 year ago

OS Therapies Inc trading resumes


gabriel6748
gabriel6748 Jul. 15 at 9:37 AM
$OSTX VAMOOOS! Lets gooooo! https://www.mmm-online.com/news/animal-pharma-70b-story-to-tell/ https://x.com/ostherapies/status/2077109498934607950?s=46
0 · Reply
Bangerstocksbuyer
Bangerstocksbuyer Jul. 14 at 11:55 PM
$OSTX Looking to start a position here any opinions of how derisked it is?
1 · Reply
TeaBaggerVance
TeaBaggerVance Jul. 14 at 9:43 PM
$OSTX Potential Catalyst Calendar 📅 Jul 21-Aug 8: FDA Type B Statistical Methods Meeting Potential Reaction: +15% to +40% if FDA aligns on biomarkers & 3-year OS strategy. 📅 Late Jul-Aug: FDA Meeting Results PR Potential Reaction: +10% to +30% if management confirms a clear Accelerated Approval pathway. 📅 Late Aug-Early Sep: Pre-BLA FDA Meeting Potential Reaction: +20% to +100%+ if FDA provides positive feedback and no major issues. 📅 Early-Mid Sep: 3-Year Interim Overall Survival Data Potential Reaction: +30% to +100%+ if efficacy remains statistically compelling. 📅 Late Sep: EMA Submission + Australia Phase 3 Initiation Potential Reaction: +10% to +25% as global regulatory progress is validated. 📅 Oct-Nov: Additional FDA/BLA Updates Potential Reaction: +10% to +30% depending on the nature of the update. 📅 Nov-Dec: Accelerated Approval BLA Submission Potential Reaction: +20% to +60% as the company reaches a major regulatory milestone. These are just specific to OST-HER2 😲
4 · Reply
smallpower17
smallpower17 Jul. 14 at 6:22 PM
$OSTX $BCTX OSTX and BCTX are my two picks to skyrocket between now and the end of the year. Each has a survival rate catalyst due in the 2nd half of 2026, and both look highly likely to achieve their clinical targets and get approved. Also, both have secured cash runways to get them into 2027.
0 · Reply
VinEuro
VinEuro Jul. 14 at 2:06 PM
$OSTX What is the bull-case out here, does anyone has an overview of te potential catalyst (add on my DD)
2 · Reply
Indycolts2004
Indycolts2004 Jul. 14 at 11:28 AM
0 · Reply
Wyoming2
Wyoming2 Jul. 13 at 2:29 PM
0 · Reply
cwork
cwork Jul. 13 at 2:27 PM
$OSTX https://ir.ostherapies.com/news-events/press-releases/detail/118/os-animal-health-announces-peer-reviewed-publication-of
0 · Reply
Greenbackisback
Greenbackisback Jul. 13 at 12:06 AM
$OSTX ok let’s start to make it happen this week! I am ramped up on shares and amped up!
0 · Reply
ACstranger
ACstranger Jul. 12 at 10:30 AM
$OSTX Companies do this to align with the FDA early on. By getting FDA alignment on PD biomarkers through the BEST Glossary, a company can often use these biomarkers as "surrogate endpoints" (substitute measures for clinical benefits). This can significantly shorten clinical trial times and strengthen applications for faster regulatory approvals (such as an Accelerated Approval pathway).
0 · Reply
My_Lai_1968
My_Lai_1968 Jul. 10 at 6:15 PM
$OSTX Don't forget to watch the Max Holloway vs. Conor Mcgregor fight on Saturday night, if you are able to. It "should" be a good one.
1 · Reply
smallpower17
smallpower17 Jul. 10 at 5:52 PM
$OSTX I think that we are back in a very good spot after getting past this recent unwarranted (no pun intended) freak out over more good news. Back to patiently waiting for the really great news coming this Fall and Winter - maybe we run way higher in advance of that, maybe not. But I really don't care because it's safe, it works great and saves lives, and it's going to get approved very soon by multiple of the largest jurisdictions in the world (as Roth Capital highlighted earlier this week). End of story. Take it to the bank.
1 · Reply
Liogical
Liogical Jul. 10 at 5:29 PM
$OSTX about to turn green
0 · Reply
Cowboys1
Cowboys1 Jul. 10 at 3:00 PM
$OSTX https://x.com/OSTherapies/status/2075586633605222721
1 · Reply
rocketwisher
rocketwisher Jul. 10 at 7:44 AM
$OSTX instant pullback after a lil raise..
2 · Reply
tarareba
tarareba Jul. 10 at 3:39 AM
$OSTX Showing love from Japan! 🇯🇵🧫 I’m deeply in love with the MOA of OST-HER2, but OST-503 is where the REAL insanity begins! The potential for solid tumors is mind-blowing. This is a true platform company under Dr. Craig. Loading up more! 🚀 Bullish! Bullish! 🐂
3 · Reply
topstockalerts
topstockalerts Jul. 9 at 11:39 PM
$OSTX this is starting to look like a trend, not just a bounce
0 · Reply
BillionerOfKing
BillionerOfKing Jul. 9 at 7:37 PM
$OSTX Current Stock Price: $1.66
0 · Reply
Cowboys1
Cowboys1 Jul. 9 at 7:37 PM
$OSTX https://x.com/G_Commish/status/2075225693852426317
1 · Reply
Bigbartabs61
Bigbartabs61 Jul. 9 at 7:08 PM
$OSTX I just wanted to point out to everyone that mentions delays, the 3-year overall survival data doesn't even mature until Sep 21. It will no-doubt be submitted as soon as it is possible to compile and validate it. That has always been the hard date, gating item. The phase 3 is planned to begin in late September. But they also need to get the FDA to commit to rolling review via these upcoming meetings.
0 · Reply
Cowboys1
Cowboys1 Jul. 9 at 6:54 PM
$OSTX This analyst upgrade will have legs... $2.50 by the end of the month wouldnt be bad.
0 · Reply
nik4
nik4 Jul. 9 at 4:58 PM
$OSTX For OSTX, the sequence is expected to be: Summer 2026: Type B Statistical Methods Meeting. Early Fall 2026: Type B Pre-BLA Meeting. Later in Fall 2026 (if all goes as planned): Submit the BLA. About 60 days later: FDA decides whether to accept the BLA for review. 6 months after acceptance: PDUFA date (the FDA's target decision date).
1 · Reply